Dr. Feldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
92 Second Street
Hackensack, NJ 07601- Is this information wrong?
Summary
- As an attending physician in the Lymphoma Division and director of the T-Cell Lymphoma Program at John Theurer Cancer Center, I am optimistic that current research into intercellular mechanisms can generate effective new therapies for treating this rare type of lymphoma. Immunotherapy, specifically CAR-T 19 cells that are genetically modified to attack lymphoma cells, is an especially exciting new approach.
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2001
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
- Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 1995 - 1999
- Minsk Medical InstituteClass of 1992
Certifications & Licensure
- NY State Medical License 1998 - 2026
- NJ State Medical License 2002 - 2025
- DC State Medical License 2019 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2016
- Top Doctors: New York Metro Area Castle Connolly, 2014
- Inside Jersey Top Doctors for Cancer Castle Connolly, 2014
- Join now to see all
Clinical Trials
- Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL Start of enrollment: 2010 Oct 01
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 37 citationsAllogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo
Haematologica. 2023-01-01 - 1160 citationsChemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chime...James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert Somerville, Robert O. Carpenter
Journal of Clinical Oncology. 2015-02-20 - 417 citationsBrentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven M. Horwitz, Owen A. O'Connor, Barbara Pro, Timothy M Illidge, Michelle A. Fanale
Lancet. 2019-01-19
Abstracts/Posters
- Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyTatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.2019 ASCO Annual Meeting - 6/1/2019
- Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- 2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
- N.J.’s 2021 Top Cancer Doctors Lead Charge to Help Patients Thrive and Survive After PandemicJune 17th, 2021
- John Theurer Cancer Center's Dr. Andre Goy Co-Chairs 21st Annual International Congress on Hematologic MalignanciesFebruary 27th, 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Russian
Hospital Affiliations
- Hackensack Meridian Health Hackensack University Medical CenterHackensack, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: